ACOG Releases Guideline on Gestational Diabetes
Am Fam Physician. 2014 Sep 15;90(6):416-417.
Key Points for Practice
• Screening for gestational diabetes usually occurs at 24 to 28 weeks' gestation, but early screening is recommended in women with risk factors.
• Gestational diabetes should be treated with nutrition therapy.
• If medications are needed, insulin and oral medications are equally effective and appropriate for first-line therapy.
• Women with gestational diabetes should be screened again at six to 12 weeks postpartum.
From the AFP Editors
Up to 7% of pregnancies are complicated by diabetes mellitus, and rates of gestational diabetes are rising worldwide with the increase in obesity and sedentary lifestyle. Gestational diabetes increases the risk of gestational hypertension, preeclampsia, cesarean delivery, and developing diabetes later in life. There is debate about the diagnosis and treatment of gestational diabetes, even with large-scale studies on the subject. The American College of Obstetricians and Gynecologists (ACOG) has released a guideline that provides recommendations based on good-quality research and identifies current gaps in knowledge.
GOOD AND CONSISTENT EVIDENCE
Gestational diabetes should be treated with nutrition therapy. If necessary, medications should also be used to benefit the mother and fetus.
Studies show a significant reduction in serious complications with treatment of gestational diabetes. Nutrition therapy includes nutritional counseling, a personalized nutrition plan, and a moderate exercise program, with the goal of achieving normoglycemia, preventing ketosis, facilitating adequate weight gain, and contributing to fetal well-being.
If target glucose levels cannot be met with nutrition therapy alone, medical therapy should be initiated. There is no conclusive evidence to guide when to start medications. Although insulin has been the standard medical therapy for gestational diabetes, insulin and oral medications (e.g., glyburide, metformin [Glucophage]) are equally effective and appropriate for first-line therapy.
LIMITED OR INCONSISTENT EVIDENCE
All pregnant women should be screened for gestational diabetes using history, clinical risk factors, or glucose screening tests. Screening for gestational diabetes usually occurs at 24 to 28 weeks' gestation. Early screening is recommended in women with risk factors (i.e., history of gestational diabetes, known impaired glucose metabolism, or obesity [body mass index of 30 or more]). If early screening results are negative, screening should be repeated at 24 to 28 weeks' gestation. The screening approach widely used in the United States involves an initial venous glucose measurement one hour after administration of 50 g of oral glucose solution. Women who meet or exceed the screening threshold in the initial test then undergo a 100-g, three-hour oral glucose tolerance test.
Although there are insufficient data to recommend for or against cesarean delivery in cases of suspected macrosomia to reduce birth trauma, macrosomia is more common with gestational diabetes, and shoulder dystocia is more common in larger newborns whose mothers have gestational diabetes. Therefore, it is reasonable to discuss the option of cesarean delivery if gestational diabetes is diagnosed and the fetal weight is estimated at 4,500 g (9 lb, 15 oz) or more.
CONSENSUS AND EXPERT OPINION
Screening thresholds for the one-hour glucose challenge have ranged from 130 mg per dL (7.2 mmol per L) to 140 mg per dL (7.8 mmol per L), showing varying sensitivities and specificities. Because there is no clear evidence to determine the best threshold, physicians should select either 135 mg per dL (7.5 mmol per L) or 140 mg per dL as a single consistent cutoff for their practice. Factors such as community prevalence of gestational diabetes should be considered in the decision. Similarly, no one set of diagnostic criteria can be recommended for the three-hour oral glucose tolerance test. Physicians should choose a single set of diagnostic criteria to use consistently in their practice: plasma or serum glucose levels designated by the Carpenter and Coustan criteria, or the plasma levels established by the National Diabetes Data Group.
After gestational diabetes is diagnosed and nutrition therapy begins, blood glucose should be monitored to establish whether glucose levels are sufficiently controlled. Although there is insufficient evidence to determine the optimal frequency of glucose monitoring, the general recommendation is four times daily (fasting and one or two hours after each meal). Monitoring can be adjusted after glucose levels are well controlled by diet.
Women with gestational diabetes who have good glycemic control and no other complications can be treated expectantly. Most women with good glycemic control on medical therapy do not require delivery before 39 weeks' gestation.
All women with gestational diabetes should be screened six to 12 weeks postpartum for diabetes, impaired fasting glucose, or impaired glucose tolerance. Women with positive screening results should be referred for preventive therapy, and women with negative screening results should receive follow-up testing every three years. A fasting plasma glucose test or a 75-g, two-hour oral glucose tolerance test is appropriate for postpartum screening.
Guideline source: American College of Obstetricians and Gynecologists
Evidence rating system used? Yes
Literature search described? Yes
Guideline developed by participants without relevant financial ties to industry? Not reported
Published source: Obstetrics & Gynecology, August 2013
Coverage of guidelines from other organizations does not imply endorsement by AFP or the AAFP.
A collection of Practice Guidelines published in AFP is available at https://www.aafp.org/afp/practguide.
Copyright © 2014 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Apr 1, 2020
Access the latest issue of American Family Physician